Current Report Filing (8-k)
26 July 2022 - 6:49AM
Edgar (US Regulatory)
0001533743
false
0001533743
2022-07-19
2022-07-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 19, 2022
PROCESSA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware |
|
001-39531 |
|
45-1539785 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
|
|
7380
Coca Cola Drive, Suite 106,
Hanover,
Maryland |
|
21076 |
|
|
(Address
of Principal Executive
Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (443) 776-3133
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
PCSA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On
July 19, 2022, the Board of Directors of Processa Pharmaceuticals, Inc. (the “Company”) appointed James R. Neal to its Board
of Directors, effective immediately. Mr. Neal will serve until the Processa Pharmaceuticals, Inc. 2023 Annual Meeting of Shareholders,
or until the earlier of: his
death, resignation or removal.
Mr.
Neal, age 66, is currently the Chief Executive Officer and Chairman of the Board for XOMA, Inc. Mr. Neal serves on the Board of Directors
of Palisade Bio, Inc., a clinical-stage biopharmaceutical company, where he is part of their Compensation Committee and is also Chairman
of the Board of Directors of Monterey Bio Acquisition Corporation. The Board elected Mr. Neal because of his extensive experience in
the life sciences industry and experience with public companies.
Mr.
Neal will be compensated according to Company’s compensation program for non-employee directors as described in the Company’s
Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 31, 2022.
Item
9.01(d) |
Financial
Statements and Exhibits |
104 |
Cover
Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
PROCESSA
PHARMACEUTICALS, INC. |
|
|
|
Date:
July 25, 2022 |
By: |
/s/
James Stanker |
|
|
James
Stanker |
|
|
Chief
Financial Officer |
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Jul 2023 to Jul 2024